ReShape Lifesciences (HIND) EBITDA (2015 - 2026)
ReShape Lifesciences (HIND) EBITDA from Sep 30, 2015 to Mar 31, 2026. The TTM ReShape Lifesciences (HIND) EBITDA is -$11M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
ReShape Lifesciences (HIND) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 3 Years TTM | -36.11% |
| 5 Years TTM | +3.66% |
| 10 Years TTM | +5.03% |
| All Time TTM | -0.32% |
Annual EBITDA change of ReShape Lifesciences (HIND)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$1.13M | -89.18% |
| 2025 | -$10M | +954.55% |
| 2024 | -$990K | -93.51% |
| 2023 | -$15M | -66.84% |
| 2022 | -$46M | -20.17% |
| 2021 | -$58M | +375.66% |
| 2020 | -$12M | -46.73% |
| 2019 | -$23M | -39.12% |
| 2018 | -$37M | +9.72% |
| 2017 | -$34M | +76.39% |
| 2016 | -$19M | +30.74% |
| 2015 | -$15M | +52.74% |
| 2014 | -$9.67M | N/A |
Comparison ReShape Lifesciences (HIND) five years EBITDA CAGR with competitors
ReShape Lifesciences (HIND) five years EBITDA CAGR is 3.66%.